Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Kathryn A. Gold, MD
Advertisement
Articles by Kathryn A. Gold, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerPublished: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
3
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
4
Enfortumab Vedotin Combo Improves Survival in Cisplatin-Eligible MIBC
5